Retifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study

Berton, Dominique; Pautier, Patricia; Lorusso, Domenica; GENNIGENS, Christine; Gladieff, Laurence; Kryzhanivska, Anna; Ranganathan, Sulabha; Tian, Chuan; Bourayou, Nawel; Vergote, Ignace

Poster (Scientific congresses and symposiums)

Berton, Dominique; Pautier, Patricia; Lorusso, Domenica et al.

2021 • Society for Immunotherapy of Cancer's 36th Annual Meeting

Permalink
https://hdl.handle.net/2268/265213

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Retifanlimab in Patients With Recurrent MSI-H or dMMR Endometrial Cancer.pdf

Publisher postprint (649.43 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Oncology

Author, co-author :

Berton, Dominique

Pautier, Patricia

Lorusso, Domenica

GENNIGENS, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale

Gladieff, Laurence

Kryzhanivska, Anna

Ranganathan, Sulabha

Tian, Chuan

Bourayou, Nawel

Vergote, Ignace

Language :

English

Title :

Retifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study

Publication date :

10 November 2021

Event name :

Society for Immunotherapy of Cancer's 36th Annual Meeting

Event place :

Wasthington, United States - District of Columbia

Event date :

10-14 novembre 2021

Audience :

International

Available on ORBi :

since 22 November 2021

Statistics

Number of views

60 (4 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics